Skip to main content
Menu

In Silico

IBM’s Watson Does Drug Discovery?

I saw this story this morning, about IBM looking for more markets for its Watson information-sifting system (the one that performed so publicly on “Jeopardy”. And this caught my eye for sure:

John Baldoni, senior vice president for technology and science at GlaxoSmithKline, got in touch with I.B.M. shortly after watching Watson’s “Jeopardy” triumph. He was struck that Watson frequently had the right answer, he said, “but what really impressed me was that it so quickly sifted out so many wrong answers.”
That is a huge challenge in drug discovery, which amounts to making a high-stakes bet, over years of testing, on the success of a chemical compound. The failure rate is high. Improving the odds, Mr. Baldoni said, could have a huge payoff economically and medically.
Glaxo and I.B.M. researchers put Watson through a test run. They fed it all the literature on malaria, known anti-malarial drugs and other chemical compounds. Watson correctly identified known anti-malarial drugs, and suggested 15 other compounds as potential drugs to combat malaria. The two companies are now discussing other projects.
“It doesn’t just answer questions, it encourages you to think more widely,” said Catherine E. Peishoff, vice president for computational and structural chemistry at Glaxo. “It essentially says, ‘Look over here, think about this.’ That’s one of the exciting things about this technology.”

Now, without seeing some structures and naming some names, it’s completely impossible to say how valuable the Watson suggestions were. But I would very much like to know on what basis these other compounds were suggested: structural similarity? Mechanisms in common? Mechanisms that are in the same pathway, but hadn’t been specifically looked at for malaria? Something else entirely? Unfortunately, we’re probably not going to be able to find out, unless GSK is forthcoming with more details.
Eventually, there’s coing to be another, somewhat more disturbing answer to that “what basis?” question. As this Slate article says, we could well get to the point where such systems make discoveries or correlations that are correct, but beyond our ability to figure out. Watson is most certainly not there yet. I don’t think anything is, or is really all that close. But that doesn’t mean it won’t happen.
For a look at what this might be like, see Ted Chiang’s story “Catching Crumbs From the Table”, which appeared first in Nature, and then in his collection Stories of Your Life and Others, which I highly recommend, as “The Evolution of Human Science”.

32 comments on “IBM’s Watson Does Drug Discovery?”

  1. patentgeek says:

    Eventually, AIs will progress to proposing de novo novel compounds for evaluation, and some will be successful. I hope I’m around for the gnarly questions on inventorship under US law that will occur when that happens. “…beyond our ability to figure out.” Heh-heh.
    Derek’s recommendation re Ted Chiang is strongly recommended!! His “The Merchant and the Alchemist’s Gate” is a modern-day Arabian Nights tour de force.

  2. josh bloom says:

    I’ll take “Lipinski Violators” for 400, Alex.

  3. oldtimer says:

    Hmmm, teams of bright PhDs with tons of experience, and insight wade through a great deal of poorly validated (clinically) biological data and progress compounds to the clinic where for the most part they fail. What makes you think that Watson or any other expert system will do better? It is not the sifting of the data that is the issue, it is the quality of and validity of the data.

  4. Foolery says:

    There is another Slate article here: http://www.slate.com/articles/technology/robot_invasion/2011/09/robot_invasion_can_computers_replace_scientists_.html
    The program, Eureqa, has actually come up with an analysis of cellular behavior that holds true and is currently unexplainable.

  5. anon the II says:

    This is a crock. First of all, if those pansies at IBM were real men, they would have made that stupid Watson parse the damn questions like the two humans had to do. The technology is certainly there for a camera to read the board, do the ICR and feed the answers into Watson’s search engine. But Noooooo. They got the answer fed from a text file straight into Watson’s feeble brain. So while Jennings and that other sap are trying to read the first character in the answer, Watson was already scanning the databanks and slamming the button. I was embarrassed for science to watch that crap and hear it called competition.
    When the battle comes, I’m siding with the humans.

  6. gippgig says:

    This would probably work reasonably well for things drugs all have in common, such as finding compounds with low toxicity, good pharmacokinetics, etc. Predicting compounds with totally new modes of action would probably require much more detailed information on how cells function at the molecular level then is available. Maybe in a few decades…

  7. Watson: I am sorry Dave, I cannot let you synthesize that compound.

  8. Watson: I am sorry Dave, I cannot let you synthesize that compound.

  9. Mad Dog says:

    @7: Are you implying Watson is one of the Pfizer “designers”?

  10. darwinsdog says:

    The day a computer does anything more than tell the programmer the same thing they could have calculated themselves but just in a faster manner is the day I…hey wait…uh, Google what do you mean ‘self aware’..I didn’t ask…easy now…[EXTERMINATE !, EXTERMINATE !]

  11. metaphysician says:

    It may not be yet, but it is a legitimate matter of discussion for the future. I would say that it should only qualify as a “designer” for the purposes of patents if it also qualifies as a *person*, and is thus as much an employee of the company as any human. Of course, that is its own giant massive ball of wax. . .

  12. josh bloom says:

    @Curious– VERY funny

  13. matt says:

    Yes, but can Watson avoid embarrassing gaffes or prove that overexposure to antioxidants is contributing to cancer rates?

  14. ex-GSK says:

    Bet Watson could shift through the Sirtris data and suggest the company was worth somewhat less than the $750M GSK spent for them…. But then, so did the due diligence team at GSK. You have to actually base decisions on data to care.

  15. Anonymous says:

    Well if John Baldoni thinks it’s worth investigating, it must be good!

  16. hibob says:

    We’ve ” been there” ever since genetic algorithms were introduced: completely impenetrable code and decision making. The jump is when the questions getting correctly answered are ones we have no understandable way of solving, as opposed to being merely difficult.

  17. Insilicoconsulting says:

    Look upon it as a very efficient form of search, given the right parameters(human experts), the right data and background knowledge .
    It may outperform human intuition in terms of lesser false positives and negatives, but we would still be the ones defining the context and prior knowledge fed to the beast.

  18. Anonymous says:

    John Baldoni…….! A lot of people @GSK are rolling around the floor laughing! Perhaps the Great Baldoni will invest in a Watson and sack a few scientists to make room for it.

  19. I’m struck by the fact that this may soon create “obvious” solutions for the pharma industry, meaning no more patents – “It’s obvious to ask Watson and then try what he suggests.” After all, this is well within the capabilities of the iconic PHOSITA (Person Having Ordinary Skill In The Art)

  20. TheGreatBaldoni says:

    Would the real Baldoni please stand up?
    Is it this one? http://www.baldoni.dk/
    or this one? http://www.amazon.com/John-Baldoni/e/B001IXS1FO/ref=sr_ntt_srch_lnk_1?qid=1362148054&sr=1-1

  21. anon says:

    would all the junk research out there be included too? and would Watson know to ignore it?

  22. Woos? says:

    Let Watson seat at any GSK portfolio review meeting and he will perform like everybody else in term of probability of success.

  23. watcher says:

    My bet is the Watson found what any good chemist and biologist team would do when looking under the lamp post. Can it actually move the vision? Unlikely.

  24. simpl says:

    agree with 16
    We saw this with visual control of vial production. There was no way the first generation of machines could match human skill. But over thirty years, the makers have made enough progress that the job is now better done by machine.

  25. jimrandomh says:

    My guess is that the 15 candidate drugs it suggested were, in fact, mentioned as candidates by papers in the dataset. That is, in fact, a pretty good way of finding candidate drugs (as long as no one else got there first), but it’d be a case of Watson acting like the fancy search engine that it is, and not like the AI its PR claims.

  26. Watson is probably well into the black box mode.
    I think we need to start to become comfortable with the fact that computers can have amazing intuitions: correct inferences that are impossible to rationalize.

  27. MoMo says:

    Not impressed. They fed the scientific literature, primarily chemical and biological abstracts, and came up with only 15 new anti-malarials? One can do the same with Scifinder and use Tanimoto similarity searches to do the same thing. In about 15 minutes and using a laptop.
    Good waste of time, Watson.

  28. DCRogers says:

    Beware of “uninterpretable” AI models.
    I’m reminded of a story (perhaps apocryphal) of a university that wanted a filter for the mountains of applicants. They used Machine Learning to build a complex AI model that did as good a job sifting the candidates as did their human experts, in a fraction of the time.
    Punch line: they got sued for sex discrimination. They said, hey, not possible, we’re using AI! Belatedly looking into the complex model, they found to their chagrin logic something like:
    IF (SEX EQ ‘F’) THEN
    SCORE = SCORE – 10;
    ENDIF;

  29. metaphysician says:

    #28-
    Of course, that opens some very interesting questions: what if an objective, unbiased AI *does* turn up logic like that in its statistical assessments? Is it discrimination if it can be actuarially supported?

  30. hibob says:

    #29:
    “Is it discrimination if it can be actuarially supported?”
    It could still be discrimination if underperformance by women at the university was due to actions by that university as opposed to the nature of the applicants/students.
    Legally allowed? Sex falls under intermediate scrutiny, but the Supreme Court normally puts it at the end of intermediate scrutiny that’s closest to strict scrutiny.
    Probably not.

  31. A. Postdoc says:

    A total crock. Science by press release is awful. Drawing attention to this diminishes all the efforts of people doing real virtual screening with actual followup testing. Derek, I think you should try to highlight some of those.

  32. MIMD says:

    See:
    “To Save Everything, Click Here: The Folly of Technological Solutionism”
    http://www.amazon.com/Save-Everything-Click-Here-Technological/dp/1610391381

Comments are closed.